Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time

Summary:

• Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines, with strong revenue from Keytruda and Gardasil despite challenges in China.
• Strategic acquisitions and partnerships, including Acceleron, Prometheus, and Daiichi Sankyo, bolster Merck’s drug pipeline and expand its oncology and cardiovascular portfolios.
• Merck’s robust R&D efforts and wide moat, supported by a strong dividend yield and A+ S&P credit rating, make it a compelling buy.
• Despite regulatory risks and patent disputes, Merck’s earnings are projected to rise, with significant growth expected in 2025 and beyond.
• Rose Take and Recommendation for purchase is given along with the Chowder #.

Global drug manufacturer Merck & Co. was founded in 1891 in Rahway, New Jersey where it is also headquartered. It operates worldwide primarily providing pharmaceutical prescription drugs along with some animal health products. Originally it was founded in 1668 in Germany

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MRK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Macro Trading Factory is a macro-driven service, run by a team of experienced investment managers.

The service offers two portfolios: “Funds Macro Portfolio” & “Rose’s Income Garden”; both aim to outperform the SPY on a risk-adjusted basis, in a relaxed manner.

Suitable for those who either have little time/knowledge/desire to manage a portfolio on their own, and/or wish to get exposed to the market in a simple, though more risk-oriented (less volatile), way.

Each of our portfolios, spanning across all sectors, offers you a hassle-free, easy to understand and execute, solution.

Macro Trading Factory for an Upward Trajectory!